(PRESS RELEASE) IRVINE, CA — Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, announced the appointment of José Trevejo, M.D., Ph.D., as Chief Medical Officer. Dr. Trevejo brings over 20 years of experience advancing the clinical development of novel therapeutics for serious diseases. Dr. Trevejo’s leadership will be highly valued in the continued advancement of TP-03, the Tarsus pipeline programs in eye care, dermatology and infectious diseases, and pipeline expansion opportunities.
“We are delighted to welcome Dr. Trevejo to the Tarsus team at this key point in the company’s growth, as we complete the second pivotal clinical trial for our lead investigational product, TP-03, for the treatment of Demodex blepharitis, and if results are positive, expect to submit a New Drug Application (NDA) later this year,” said Bobak Azamian, M.D., Ph.D., President and Chief Executive Officer of Tarsus Pharmaceuticals. “Dr. Trevejo’s leadership in drug development and clinical trials will be instrumental in advancing TP-03 towards FDA approval as well as expanding our broader pipeline. Additionally, his deep infectious disease expertise will be particularly impactful in furthering our novel anti-parasitic platform across several indications, including our Lyme disease prevention, community malaria reduction, rosacea and meibomian gland disease treatment programs.”
Before joining Tarsus, Dr. Trevejo served as Chief Development Officer at Rocket Pharmaceuticals and as CEO of a gene therapy company, SmartPharm. Prior to SmartPharm, he was the Vice President, Clinical Development at Cyclerion Therapeutics (previously a division of Ironwood Pharmaceuticals). Dr. Trevejo joined Cyclerion from Visterra, where he was a member of the Executive Team and led the pre-clinical and clinical development of novel biologics for infectious and rare diseases. Prior to Visterra, he held clinical development roles at Genentech and Vertex Pharmaceuticals.
“I am honored to join Tarsus during this exciting time for the company,” said Dr. Trevejo. “Tarsus has a robust pipeline of therapies in development, and I look forward to advancing the clinical programs, contributing to the development of these innovative and highly anticipated therapies as well as helping to expand the pipeline.”
Dr. Trevejo completed his clinical training, including an infectious disease fellowship following an internal medicine residency at Brigham and Women’s Hospital/Beth-Israel Deaconess Hospital/Harvard Medical School. He earned his M.D. and Ph.D. degrees from the Tri-Institutional M.D.-Ph.D. program at Cornell-Rockefeller-Sloan Kettering in New York City.
